Celcuity Inc.
Business
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors, primarily focused on gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR pathway. The company's lead candidate is in Phase 3 trials for hormone receptor-positive, HER2-negative advanced breast cancer and Phase 1b/2 trials for metastatic castration-resistant prostate cancer. Gedatolisib has received FDA Fast Track and Breakthrough Therapy designations, with an NDA submitted under Real-Time Oncology Review and Priority Review, with a PDUFA goal date of July 17, 2026. The company operates clinical development programs across North America, Europe, and Asia-Pacific through a network of ~200 clinical sites.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 145 | 104 | 61 | 35 | 26 | |
| General and administrative | 27 | 9 | 6 | 4 | 3 | |
| Total operating expenses | 172 | 113 | 66 | 39 | 28 | |
| Loss from operations | −172 | −113 | −66 | −39 | −28 | |
| Interest expense | −17 | −10 | −5 | — | — | |
| Interest income | 12 | 12 | 8 | 1 | 13,262 | |
| Other (expense) income, net | −5 | 1 | 2 | — | — | |
| Net loss before income taxes | −177 | −112 | −64 | −40 | −30 | |
| Income taxes | — | — | — | — | — | |
| Net loss | −177 | −112 | −64 | −40 | −30 | |
| Net loss per share, basic | −3.79 | −2.83 | −2.69 | −2.64 | −2.21 | |
| Net loss per share, diluted | −3.79 | −2.83 | −2.69 | −2.64 | — | |
| Weighted average common shares outstanding, basic | 47 | 39 | 24 | 15 | 13 | |
| Weighted average common shares outstanding, diluted | 47 | 39 | 24 | 15 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 166 | 23 | 31 | 25 | 84 | |
| Investments | 276 | 213 | 150 | 144 | — | |
| Prepaid clinical trial costs | 19 | 7 | — | — | — | |
| Other current assets | 5 | 3 | 10 | 7 | — | |
| Total current assets | 466 | 245 | 191 | 175 | 85 | |
| Property and equipment, net | 499,000 | 336,000 | 228,782 | 260,294 | 312,444 | |
| Operating lease right-of-use assets | 51,000 | 216,000 | 400,019 | 246,266 | 241,901 | |
| Other non-current assets | 349,000 | — | — | — | — | |
| Total assets | 467 | 245 | 191 | 176 | 86 | |
| Accounts payable | 6 | 9 | 5 | 3 | 2 | |
| Accrued clinical trial costs | 17 | 17 | — | — | — | |
| Other accrued expenses | 21 | 5 | — | — | — | |
| Operating lease liabilities, current | 54,000 | 172,000 | 184,950 | 191,749 | 189,858 | |
| Total current liabilities | 44 | 32 | 14 | 7 | 3 | |
| Operating lease liabilities, non-current | — | 54,000 | 225,922 | 61,002 | 61,771 | |
| Convertible debt | 195 | — | — | — | — | |
| Note payable, non-current | 127 | 98 | 37 | 35 | 15 | |
| Total liabilities | 366 | 130 | 51 | 42 | 17 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | 854 | 1,121 | — | |
| Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 48,000 | 37,000 | 25,506 | 21,667 | 14,919 | |
| Additional paid-in capital | 549 | 387 | 300 | 230 | 125 | |
| Accumulated deficit | −449 | −272 | −160 | −96 | −56 | |
| Total stockholders equity | 101 | 116 | 140 | 134 | 69 | |
| Total liabilities and stockholders equity | 467 | 245 | 191 | 176 | 86 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 200,000 | 100,000 | 142,772 | 210,918 | 303,235 | |
| Stock-based compensation | 21 | 7 | 5 | 5 | 3 | |
| Amortization of debt issuance costs and discount | 3 | 1 | 241,752 | 395,757 | 267,821 | |
| Payment-in-kind interest | 1 | 1 | 2 | 455,074 | 300,001 | |
| Non-cash operating lease expense | −7,000 | — | 4,368 | — | — | |
| Change in accrued interest income | 630,000 | 150,000 | −993,457 | — | — | |
| Prepaid clinical trial costs | −12 | −2 | — | — | — | |
| Other current and non-current assets | −3 | 3 | −3 | −6 | — | |
| Accounts payable | −3 | 4 | 2 | 1 | 1 | |
| Accrued clinical trial costs | 118,000 | 10 | — | — | — | |
| Other accrued expenses | 15 | 3 | — | — | — | |
| Net cash used in operating activities | −153 | −83 | −54 | −36 | −20 | |
| Proceeds from maturities of investments | 333 | 642 | 310 | — | — | |
| Purchases of investments | −396 | −705 | −315 | −144 | — | |
| Purchases of property and equipment | −249,000 | −250,000 | −97,644 | −158,768 | −81,898 | |
| Net cash used in investing activities | −64 | −63 | −5 | −144 | −81,398 | |
| Proceeds from employee stock purchases | 711,000 | 276,000 | 202,845 | 171,710 | — | |
| Proceeds from exercise of common stock options | 3 | 770,000 | 388,522 | 152,412 | 63,420 | |
| Proceeds from exercise of common stock warrants | 42 | 15 | 22,505 | — | 18,762 | |
| Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively | 195 | — | — | — | — | |
| Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively | 28 | 59 | — | 20 | 14 | |
| Proceeds from equity offering, net of underwriting discounts and offering costs | 92 | 56 | — | — | — | |
| Proceeds from an ATM offering, net of issuance costs | — | 7 | 14 | — | — | |
| Payments for secondary registration statement costs | −46,000 | −228,000 | −45,805 | — | — | |
| Net cash provided by financing activities | 361 | 138 | 65 | 120 | 93 | |
| Net change in cash and cash equivalents | 143 | −8 | 6 | −60 | 73 | |
| Cash paid for interest | 10 | 8 | 3 | 1 | 694,528 | |
| Cash paid for operating leases | 220,000 | 325,000 | — | — | — | |
| Common stock warrants issued with the note payable transaction | 3 | 1 | — | — | — | |
| Property and equipment included in accounts payable | 82,000 | 1,000 | 13,615 | — | — | |
| Deferred financing, offering and registration statement costs included in accounts payable | — | 42,000 | 56,414 | 51,020 | 8,123 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Celcuity Inc.'s CIK number?
Celcuity Inc.'s SEC CIK number is 0001603454 (1603454). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Celcuity Inc.'s SEC filings?
All of Celcuity Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Celcuity Inc. last report earnings?
Celcuity Inc. (CELC) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023065). This is Celcuity Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Celcuity Inc.'s most recent earnings 8-K?
Celcuity Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-023065. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Celcuity Inc.'s latest earnings 8-K →
Look up any company's CIK number →